Efficacy and safety of omalizumab against chronic spontaneous urticaria: Real-world study from China

Efficacy and safety of omalizumab against chronic spontaneous urticaria: Real-world study from China

Background: Omalizumab is an effective treatment for chronic spontaneous urticaria (CSU) patients aged ≥12 years, but its efficacy in patients aged <12 years has not been fully documented. We evaluated the therapeutic efficacy and safety of omalizumab in Chinese CSU population across all age grou...

Full description

Bibliographic Details
Main Authors: Ao Wang, MD, Yuhui Yun, MM, Zhihua Wen, MM, Yingxia Gao, BS, Shuzhen Qi, MD, Yu Zhang, MD, Yunsheng Liang, MD, Xu Yao, MD
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:World Allergy Organization Journal
Subjects:
Chronic spontaneous urticaria
Omalizumab
Therapy
Efficacy
Pediatric patients
Online Access:http://www.sciencedirect.com/science/article/pii/S1939455122000953

Similar Items

Similar Items